In short
Elenestinib Phosphate, also known as BLU-263, is an investigational drug currently being studied in clinical trials for the treatment of Indolent Systemic Mastocytosis (ISM) and Smoldering Systemic Mastocytosis (SSM). This article explores the ongoing research into Elenestinib Phosphate's potential to improve outcomes for patients with these rare mast cell disorders.
At a glance
- Drug Name
- Elenestinib Phosphate (BLU-263)
- Conditions Studied
- Indolent Systemic Mastocytosis (ISM), Smoldering Systemic Mastocytosis (SSM)
- Trial Design
- Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study
- Primary Objectives
- Determine recommended dose, assess safety and efficacy
- Key Endpoints
- Change in ISM-SAF Total Symptom Score, serum tryptase levels, KIT D816V allele fraction
- Treatment Duration
- Up to approximately 4 years
- Dosing
- 25 mg, 50 mg, 100 mg doses tested
- Patient Population
- Adults (≥16 or ≥18 years, depending on country) with confirmed ISM or SSM
What is ELENESTINIB PHOSPHATE?
ELENESTINIB PHOSPHATE, also known as BLU-263 phosphate, is an investigational drug being developed for the treatment of certain blood disorders. It is a selective KIT inhibitor, which means it targets a specific protein involved in the growth and survival of certain cells in the body.
Medical Conditions Treated
The primary focus of the current clinical trial is on treating Indolent Systemic Mastocytosis (ISM) and Smoldering Systemic Mastocytosis (SSM). These are rare disorders characterized by the abnormal accumulation of mast cells (a type of white blood cell) in various tissues of the body.
Symptoms of ISM and SSM can include:
- Skin rashes or flushing
- Stomach pain and diarrhea
- Bone pain
- Fatigue
- Anaphylaxis (severe allergic reactions)
How ELENESTINIB Works
ELENESTINIB PHOSPHATE works by targeting the KIT protein, which is often mutated in patients with systemic mastocytosis. By inhibiting this protein, the drug aims to reduce the number of abnormal mast cells and alleviate symptoms associated with the disease.
Current Clinical Trial
A large-scale clinical trial called "HARBOR" is currently underway to evaluate the effectiveness and safety of ELENESTINIB (also referred to as BLU-263) in patients with Indolent Systemic Mastocytosis. This trial is divided into several parts:
- Part 1: A 12-week period testing different doses of ELENESTINIB
- Part 2: A longer-term study comparing ELENESTINIB to a placebo
- Part 3: An extension period for long-term safety and efficacy assessment
- Part S: An exploratory study for patients with Smoldering Systemic Mastocytosis
Dosage and Administration
In the clinical trial, ELENESTINIB is being tested at various doses, including 25 mg, 50 mg, and 100 mg. It is administered orally in the form of a film-coated tablet. The maximum daily dose being studied is 100 mg.
Who Can Participate in the Trial?
The trial is primarily looking for patients who:
- Are 16 years of age or older (18 or older in some countries)
- Have been diagnosed with Indolent Systemic Mastocytosis or Smoldering Systemic Mastocytosis
- Have moderate to severe symptoms that haven't been adequately controlled by other treatments
- Have a specific genetic mutation called KIT D816V
Patients with certain other conditions, such as aggressive systemic mastocytosis or mast cell leukemia, are not eligible for this trial.
Potential Benefits
The researchers hope that ELENESTINIB will provide several benefits for patients with ISM and SSM, including:
- Reduction in mast cell burden (the number of abnormal mast cells in the body)
- Improvement in symptoms such as skin flushing, gastrointestinal issues, and fatigue
- Better quality of life
- Reduction in the need for other medications to manage symptoms
Safety Considerations
As with any investigational drug, there may be unknown risks and side effects. The clinical trial is designed to carefully monitor patients for any adverse events. Some safety measures include:
- Regular check-ups and blood tests
- Monitoring of heart function through ECG evaluations
- Careful tracking of any side effects or unexpected reactions
It's important to note that ELENESTINIB is still being studied, and its full safety profile is not yet known. Patients considering participation in the clinical trial should discuss potential risks and benefits with their healthcare provider.